https://www.selleckchem.com/pr....oducts/mcc950-sodium
BACKGROUND Despite the well-defined role of minimal residual disease (MRD) monitoring by real-time quantitative polymerase chain reaction (RT-PCR) for RUNX1/RUNX1T1 and CBFB-MYH11 transcripts in core binding factor (CBF) acute myeloid leukemia (AML) after intensive chemotherapy, there has been a paucity of data assessing the utility of MRD monitoring at and after allogeneic hematopoietic stem cell transplantation (HSCT). METHODS Patients with CBF AML who underwent HSCT in complete remission (first or second) from January 2007
Like
Comment
Share
